Aslan Fred sold $469K of ARTV
Aslan Fred (Chief Executive Officer) sold 119,771 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 ($0.47M total) on 2026-11-17.
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Its lead product candidate, AlloNK, is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to work with monoclonal antibodies to deplete B cells. Artiva is evaluating AlloNK in clinical trials for B-cell-driven autoimmune diseases, including rheumatoid arthritis, Sjögren’s disease, systemic sclerosis, myositis, systemic lupus erythematosus and lupus nephritis. It also pursues CAR-NK product candidates, including AB-201 and AB-205, through collaborator-funded trials. Artiva develops and manufactures cell therapy candidates using a proprietary process and operates a 9,000 square foot cell production center in its San Diego headquarters. Its product candidates are intended to be pre-manufactured, frozen and ready for shipment to treatment locations. The company holds exclusive worldwide rights outside Asia, Australia and New Zealand to its programs.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Aslan Fred (Chief Executive Officer) sold 119,771 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 ($0.47M total) on 2026-11-17.
Artiva Biotherapeutics director Elizabeth Hougen resigned from the board, effective immediately. The company stated her departure was not due to any disagreements. No replacement or further details were disclosed. According to the SEC filing, this change occurred on November 11, 2026.
Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Elizabeth Hougen as a Class III Director On November 11, 2026, Elizabeth Hougen notified the Company of her
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARTV (Artiva Biotherapeutics, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ARTV coverage spans financial news, insider activity and corporate actions.
In the last 30 days, ARTV insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($987K). The most active reporter was Banerjee Subhashis, Chief Medical Officer, with 2 filings.
This is an insider open-market sale under a Form 4, which can modestly affect sentiment but is not a fundamental catalyst by itself.
Board turnover can prompt investors to reassess governance stability, though the filing provides no reason or replacement details.
Board composition change may affect governance optics, committee assignments, and investor sentiment, but no operational guidance or financial figures were provided.
The discontinuation removes a key pipeline asset, likely driving further downside pressure.
The insider sale may signal reduced confidence from the CEO, potentially pressuring the stock.
AlphAI scores every news story that mentions ARTV with an AI model for sentiment and relevance, and aggregates insider trades from Artiva Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aslan Fred (Chief Executive Officer) sold 119,771 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 ($0.47M total) on 2026-11-17.
Artiva Biotherapeutics director Elizabeth Hougen resigned from the board, effective immediately. The company stated her departure was not due to any disagreements. No replacement or further details were disclosed. According to the SEC filing, this change occurred on November 11, 2026.
Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Elizabeth Hougen as a Class III Director On November 11, 2026, Elizabeth Hougen notified the Company of her
Artiva Biotherapeutics (ARTV) shares fell 31% after discontinuing AlloNK development due to safety concerns. The company plans workforce reduction and strategic alternatives to enhance shareholder value, including potential mergers or asset sales.
Aslan Fred (Chief Executive Officer) sold 62,178 shares of Artiva Biotherapeutics, Inc. (ARTV) at $4.18 ($0.26M total) on 2026-11-02.
This week, analysts downgraded Fair Isaac (FICO) to Equal Weight with a $735 target, Artiva Biotherapeutics (ARTV) to Hold, Enphase Energy (ENPH) to Perform, Fortinet (FTNT) to Neutral, and Reddit (RDDT) to Market Perform, citing pricing, development, guidance, and traffic concerns. Shares of these companies fell significantly following the downgrades.
AstraZeneca (AZN) and Daiichi Sankyo (4568.T) won EU approval for Enhertu in breast cancer. Pfizer (PFE) expanded Talzenna-Xtandi use in prostate cancer. AbbVie (ABBV) got FDA approval for subcutaneous SKYRIZI in Crohn's disease. Artiva (ARTV) to cut 94% of workforce after halting AlloNK development. Tango (TNGX) plans 14% layoffs. Rakovina (RKV.V) and Celvion used AI to prioritize cancer types for ATR inhibitor. 60 Degrees (SXTP) partners for alpha-gal syndrome research.
Ferring Pharmaceuticals agreed to acquire Gameto for $1.4B. Gilead Sciences will buy PepStar Therapeutics' oral IL-23R inhibitor program for $1.275B. Zymeworks partnered with Roche for T-cell engager ZW209. Astellas secured an option to license Audax Biosciences' immuno-oncology asset. Teva finalized a Medicaid cost-lowering agreement. Pfizer's Talzenna gained FDA approval for prostate cancer. Artiva Biotherapeutics laid off 94% of its workforce. Star Therapeutics raised $200M in funding.
Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.
Jefferies downgraded Artiva Biotherapeutics to Hold from Buy, setting a $4 price target. This implies a 5.4% downside from the Oct 29 close of $4.23. Recent analyst price targets for the company range from $4 to $40.